GlassScriptPhysician profile
Darin R Branson
NPI 1255711909
$6,461.21
in general payments reported to CMS, 2019-2025
34 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,381 · 2022: $1,118 · 2023: $858 · 2024: $1,698 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,752 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,751.66 |
| Education | $210.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $809.63 | 2021-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $752.60 | 2021-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $657.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $642.20 | 2021-2025 | |
| Glaxosmithkline, LLC. | $614.12 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $507.72 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Axsome Therapeutics, INC. | $291.02 | 2025 | Auvelity |
| Astellas Pharma US INC | $240.19 | 2021-2025 | |
| Amgen INC. | $216.39 | 2022-2025 | Krystexxa, Repatha, Otezla |
| Vanda Pharmaceuticals INC. | $204.27 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $173.97 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Alkermes, INC. | $159.97 | 2021-2023 | Lybalvi |
| Medtronic, INC. | $145.62 | 2024 | Interstim |
| Hologic Sales and Service, LLC | $130.90 | 2024 | Aptima, Affirm Prone Biopsy System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.65 | 2021-2025 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $116.96 | 2024 | Uptravi, Opsumit |
| Pfizer INC. | $100.59 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $93.32 | 2021-2023 | Austedo |
| Phathom Pharmaceuticals, INC. | $84.89 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.19 | 2023-2024 | Xifaxan, Trulance |
| Sunovion Pharmaceuticals INC. | $64.14 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $43.20 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $32.09 | 2021-2022 | |
| Boston Scientific Corporation | $27.78 | 2021 | |
| Neurocrine Biosciences, INC. | $21.21 | 2022 | |
| Lundbeck LLC | $19.97 | 2025 | Rexulti |
| Exact Sciences Corporation | $19.77 | 2025 | The Cologuard Plus Collection Kit |
| Incyte Corporation | $16.91 | 2022 | |
| Esperion Therapeutics, INC. | $15.48 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.51 | 2021 | |
| Abbott Laboratories | $14.46 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.11 | 2023 | Quviviq |
| Endo Pharmaceuticals INC. | $13.01 | 2021 | |
| Sumitomo Pharma America, INC. | $5.43 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Branson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.